INDIA—Lupin Ltd., a renowned international pharmaceutical firm headquartered in Mumbai, has named Christoph Funke to the newly created position of Chief Technical Operations Officer.
Funke, who has over 30 years of global experience in pharmaceutical manufacturing, supply chain management, and technical operations, is well positioned to make major contributions to Lupin.
He will be based in Mumbai and would be in charge of Lupin’s Technical Operations division, which includes production, supply chain, and procurement.
Funke’s outstanding career includes executive positions at prestigious companies such as Fresenius Kabi and Strides Pharma Science.
During his tenure, he effectively supervised large-scale technological operations and industrial networks encompassing 27 sites in 19 countries.
His leadership has resulted in the creation of more than US$2 billion in value and the management of teams of over 12,500 individuals.
Funke received his engineering degree from the South Westphalia University of Applied Sciences in Germany.
Vinita Gupta, CEO, and Nilesh Gupta, MD of Lupin, both expressed their excitement about Christoph joining their executive leadership team.
They went on to remark that his exceptional accomplishments and vast skills in manufacturing, supply chain management, and technical operations highlight his critical role in achieving Lupin’s aim to improve global patient well-being.
This announcement comes shortly after Lupin received approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Doxycycline for Injection USP, 100 mg/Vial (Single-Dose Vial), a significant milestone in the company’s commitment to providing high-quality healthcare solutions.
Lupin is well-known for its wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs), which serve over 100 markets globally.
The company leads in major therapeutic segments such as cardiovascular, anti-diabetic, and respiratory, while also having a strong presence in anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health.
Notably, Lupin is the third-largest pharmaceutical business in the United States based on prescriptions, demonstrating its formidable influence in the global pharmaceutical market.
Furthermore, the company’s commitment to innovation is demonstrated by its large expenditure in research and development, which accounted for 7.9% of its revenue in FY23.
Lupin, with 15 manufacturing facilities, 7 research centers, and a dedicated team of over 20,000 experts worldwide, is consistently recognized as a ‘Great Place to Work’ in the biotechnology and pharmaceuticals sector.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
